PLEASANTON, CA--(MARKET WIRE)--Jun 25, 2007 -- Lipid Sciences, Inc. (NasdaqGM:LIPD - News) reported in a submission to the NIH (National Institutes of Health) it has met the study goal of creating a vaccine preparation for SARS (Severe Acute Respiratory Syndrome). This study was funded by the NIH under the auspices of an STTR (Small Business Technology Transfer) grant. Lipid Sciences was successful in using its novel, proprietary delipidation technology to demonstrate proof of principle of the modification of viral particles to be used in preparation of a preventive vaccine against the SARS Coronavirus -- a lipid-enveloped virus of particular concern as a Category C Agent in bio-defense applications. This study validated the hypothesis that a modified SARS viral particle could result in an enhanced immunogenic response in an animal model resulting in both neutralizing antibody and cell-mediated immune responses.
